Life science company Acucort reported, as planned, no revenue during the first quarter. The operating loss increased.Operating profit/loss was -SEK 6.8 million (-6.5). Profit/loss after tax was -SEK 6.8 million (-6.5), and per share -SEK 0.03 (-0.03). Cash flow from operating activities amounted to -SEK 3.7 million (-6.4). Cash and cash equivalents amounted to SEK 21.2 million (38.4).The major event during the period was the commercial agreement with Glenmark Pharmaceuticals, which gives Acucort access to six new markets in Europe."The agreement with Glenmark is clear proof that Zeqmelit generates genuine commercial interest beyond the Nordics," comments CEO Jonas Jönmark.The launch will take place gradually in the new markets, with Germany being the most important."Germany is by far the largest pharmaceutical market in Europe, and we use Germany as a reference country when we discuss other markets with potential commercial partners," says Jönmark.After the end of the period, it was announced that the company had reached an agreement with the US drug authority FDA regarding its iPSP – Initial Pediatric Study Plan – for Zeqmelit."Acucort stands strong with these milestones. We have significantly reduced the regulatory risk, we have a clear and concrete path to the US market, and we are building an increasingly broad commercial platform in Europe. The agreement with Glenmark and the agreement with the FDA meanthat we have a stronger negotiating position when we meet new potential partners," says Jönmark.Acucort, SEK millionQ1-2026Q1-2025ChangeNet sales0.00.0Operating profit/loss-6.8-6.5Profit/loss before tax-6.8-6.5Net profit/loss-6.8-6.5Earnings per share, SEK-0.03-0.03Cash flow from operating activities-3.7-6.4Cash and cash equivalents21.238.4-44.8%